CELC Company Profile and Key Details
NASDAQ : CELC
Celcuity
$103.79
-3.79-3.52%
At Close 4:00 PM62.58
B-ESG ScoreESG Rating
Price Chart
Stock Price Today
Celcuity Inc. (CELC) stock declined over -3.52%, trading at $103.79 on NASDAQ, down from the previous close of $107.58. The stock opened at $106.44, fluctuating between $100.63 and $108.69 in the recent session.
Stock Snapshot
107.58
Prev. Close
5.06B
Market Cap
100.625
Day Low
-26.61
P/E Ratio
-3.9
EPS (TTM)
-1.87
Cash Flow per Share
106.44
Open
48.77M
Number of Shares
108.69
Day High
78.39%
Free Float in %
4.84
Book Value
1.24M
Volume
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jul 13, 2026 | 106.70 | 108.78 | 100.63 | 103.79 | 1.26M |
| Jul 10, 2026 | 113.50 | 113.50 | 107.25 | 107.58 | 698.66K |
| Jul 09, 2026 | 108.28 | 113.74 | 108.28 | 113.51 | 980.31K |
| Jul 08, 2026 | 113.98 | 116.41 | 108.42 | 108.90 | 1.51M |
| Jul 07, 2026 | 110.44 | 117.21 | 108.93 | 115.72 | 1.44M |
| Jul 06, 2026 | 107.91 | 111.04 | 106.20 | 108.58 | 1.01M |
| Jul 02, 2026 | 105.84 | 108.32 | 102.62 | 107.95 | 906.23K |
| Jul 01, 2026 | 105.78 | 106.92 | 102.80 | 104.49 | 1.1M |
| Jun 30, 2026 | 103.63 | 105.52 | 101.19 | 104.62 | 1.09M |
| Jun 29, 2026 | 100.00 | 103.31 | 98.54 | 102.52 | 1.03M |
| Jun 26, 2026 | 96.23 | 101.24 | 95.00 | 99.95 | 2.55M |
| Jun 25, 2026 | 95.42 | 101.29 | 95.00 | 95.93 | 1.43M |
| Jun 24, 2026 | 89.64 | 96.90 | 89.64 | 96.38 | 1.04M |
| Jun 23, 2026 | 88.84 | 92.61 | 87.88 | 90.21 | 658.79K |
| Jun 22, 2026 | 88.56 | 91.27 | 87.01 | 89.93 | 884.33K |
| Jun 18, 2026 | 88.17 | 89.40 | 82.55 | 87.76 | 2.1M |
| Jun 17, 2026 | 88.07 | 88.85 | 85.59 | 88.05 | 1.21M |
| Jun 16, 2026 | 88.54 | 89.51 | 86.91 | 87.32 | 866.36K |
| Jun 15, 2026 | 89.97 | 90.61 | 86.53 | 88.24 | 1.11M |
| Jun 12, 2026 | 89.46 | 91.00 | 87.00 | 88.55 | 1.53M |
Contact Details
About Company
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
Company Information
| Employees | 155 |
| Beta | 0.16 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Stock Peers
ARGX
-1.37-0.16%
argenx SE$876.25REGN-1.43-0.22%
Regeneron Pharmaceuticals, Inc.$663.09UTHR-11.49-2.10%
United Therapeutics Corporation$535.57MDGL-5.7-1.06%
Madrigal Pharmaceuticals, Inc.$531.00VRTX-5.14-1.06%
Vertex Pharmaceuticals Incorporated$480.25KRYS-2.37-0.65%
Krystal Biotech, Inc.$363.44KRTX0.09+0.03%
Karuna Therapeutics, Inc.$329.83PRAX-10.43-3.21%
Praxis Precision Medicines, Inc.$314.56LGND-6.99-2.21%
Ligand Pharmaceuticals Incorporated$309.25ONC5.26001+1.76%
BeOne Medicines AG$303.96Company Overview
Celcuity Inc. (NASDAQ:CELC) closed at $103.79 USD, losing -$3.79 (-3.52%) from the previous close of $107.58. The stock is currently mid-range between its 52-week high and low $13.37 and $151.02. With a market capitalization of about $5.06 billion, Celcuity Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~0.16). Key stats such as the average daily volume over the past year has been around 1.38 million shares, in line with its 52-week average. Headquartered in Minneapolis, MN, Celcuity Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Brian F. Sullivan, the company employs approximately 155 people and listed since September 19, 2017. Celcuity, Inc. operates as a cellular analysis company.
Technical Performance
Short-term trend indicators are bearishly aligned (SMA20 3.74%, SMA50 4.85%, SMA200 80.63%). The stock’s 14-day RSI is 58.52 (neutral), while the ATR of 5.41 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -7.64% below its high and over 1366.93% above its low. Average 10-day trading volume of 1.15 million shares is in line with the 3-month average of 1.27 million, indicating normal recent market interest.
Valuation Metrics
Celcuity Inc. trades at a P/E ratio of -26.01, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 102.93 reflecting a rich premium to book value. The P/FCF stands at -28.53, also below market averages. Compared to sector medians, Celcuity Inc. P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.
Dividend & Fair Value
Celcuity Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.56. This means the shares are trading below this model’s fair value.
Shareholding & Insider Activity
Celcuity Inc. has 42.43 million shares outstanding. The public float is 18.70 million shares, elevated short interest at 14.88% of float. This equals 5.62 million shares. The short ratio is 3.62 days. Institutional investors hold 95.09% of the float. Insiders own 12.04%. Sullivan Brian F. holds 3.02 million shares, BAKER BROS. ADVISORS LP has 703.92 thousand shares and NIGON RICHARD has 96.03 thousand shares. Over the past six months, insider transactions show net selling. They sold 46.04 thousand shares across 4 transactions.
Financial & Profitability Overview
On valuation metrics, Celcuity trades at a P/E of -26.01, P/S of 0.00 and P/B of 102.93. The current ratio is 12.31 and quick ratio is 12.31. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -81185.32 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 3.65, supported by a cash flow-to-debt ratio of -0.88.
Quarterly Financial Highlights
The company ended the quarter with $180.58M in cash and short-term investments, a total debt of $37.45M, and net debt of $6.78M. Total assets were $191.22M, with equity of $139.77M. Financials further reflected weakness, with operating cash flow of - $53.81M, free cash flow of - $53.91M, and capital expenditures of - $97.64K.
Frequently Asked Questions
What is the current Celcuity Inc. (CELC) stock price?
Celcuity Inc. (NASDAQ: CELC) stock price is $103.79 in the last trading session. During the trading session, CELC stock reached the peak price of $108.69 while $100.63 was the lowest point it dropped to. The percentage change in CELC stock occurred in the recent session was -3.52% while the dollar amount for the price change in CELC stock was - $3.79.
CELC's industry and sector of operation?
The NASDAQ listed CELC is part of Biotechnology industry that operates in the broader Healthcare sector. Celcuity Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of CELC?
Ms. Vicky Hahne
Chief Financial Officer
Mr. Igor Gorbatchevsky M.D.
Chief Medical Officer
Mr. Brian F. Sullivan
Co-Founder, Chairman & Chief Executive Officer
Mr. Eric Lindquist
Chief Bus. Officer
Dr. John R. MacDonald Dabt, Ph., Ph.D.
Senior Vice President of R&D
Ms. Sheri Smith
Acting Head of Clinical Operations
Dr. Lance G. Laing Ph.D.
Co-Founder, Chief Science Officer, Vice President, Sec. & Director
Chief Financial Officer
Mr. Igor Gorbatchevsky M.D.
Chief Medical Officer
Mr. Brian F. Sullivan
Co-Founder, Chairman & Chief Executive Officer
Mr. Eric Lindquist
Chief Bus. Officer
Dr. John R. MacDonald Dabt, Ph., Ph.D.
Senior Vice President of R&D
Ms. Sheri Smith
Acting Head of Clinical Operations
Dr. Lance G. Laing Ph.D.
Co-Founder, Chief Science Officer, Vice President, Sec. & Director
How CELC did perform over past 52-week?
CELC's closing price is 676.58% higher than its 52-week low of $13.37 where as its distance from 52-week high of $151.02 is -31.27%.
How many employees does CELC have?
Number of CELC employees currently stands at 155.
Link for CELC official website?
Official Website of CELC is: https://www.celcuity.com
How do I contact CELC?
CELC could be contacted at phone 763 392 0767 and can also be accessed through its website. CELC operates from 16305 36th Avenue North, Minneapolis, MN 55446, United States.
How many shares of CELC are traded daily?
CELC stock volume for the day was 1.24M shares. The average number of CELC shares traded daily for last 3 months was 1.38M.
What is the market cap of CELC currently?
The market value of CELC currently stands at $5.06B with its latest stock price at $103.79 and 48.77M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep